Murine Model for Neonatal Necrotizing Enterocolitis Transfusion Study
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a lack of robust preclinical models to understand the mechanisms of necrotizing enterocolitis (NEC), particularly in relation to red blood cell transfusions, which hinders the development of effective treatments due to unclear causality and quality of evidence from retrospective observational studies.
Innovation Solution
A murine model of neonatal necrotizing enterocolitis is developed by inducing anemia in mice and administering red blood cell transfusions, allowing for the measurement of symptoms such as intestinal inflammation and bowel injury, and the identification of agents for prevention or treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If red blood cell transfusions are administered to anemic premature infants, then anemia is treated, but necrotizing enterocolitis (NEC) may be triggered
Solution Approach 1:
The patent applies preliminary action by inducing anemia and administering probiotics or other protective measures before the transfusion occurs. This prepares the intestinal environment to resist the harmful effects of transfusion, thereby preventing NEC while still allowing the beneficial anemia treatment to proceed
Solution Approach 2:
The patent uses intermediaries such as probiotics, prebiotics, or other protective agents that mediate between the transfusion and the intestinal tissue. These intermediaries modify the intestinal environment to reduce susceptibility to transfusion-induced injury, allowing both anemia treatment and intestinal protection
2Loss of information
If retrospective observational studies are conducted to investigate NEC mechanisms, then clinical associations can be identified, but causality and evidence quality remain unclear
Solution Approach 1:
The patent creates a murine model that copies the clinical scenario of anemia plus transfusion in premature infants. This animal model replicates the key features of human NEC, allowing researchers to study causality and mechanisms in a controlled experimental setting rather than relying on observational human data
Solution Approach 2:
The patent changes the experimental parameters from observational human studies to controlled animal experiments. By controlling variables such as anemia severity, transfusion timing, and intestinal protective measures in mice, the study can establish causality and generate high-quality evidence that cannot be obtained through retrospective human studies
3Reliability
If a robust preclinical model is developed to study NEC mechanisms, then treatment development can advance, but model complexity and preparation requirements increase
Solution Approach 1:
The patent segments the model development into distinct components: anemia induction protocol, transfusion protocol, and intestinal injury assessment methods. This segmentation allows each component to be optimized and validated independently, making the overall complex model more manageable and reproducible
Solution Approach 2:
The patent creates a multi-functional murine model that can simultaneously study multiple aspects of NEC: anemia physiology, transfusion effects, intestinal inflammation, and potential therapeutic interventions. This universal model replaces the need for multiple separate studies, justifying the initial complexity by providing comprehensive research capabilities
Data Source
AI summary
The disclosure provides methods of generating a murine model of neonatal necrotizing enterocolitis, whereby the generated murine animal exhibits at least one symptom of neonatal necrotizing enterocolitis. The disclosure also provides methods to measure transfusion effects on anemia and methods for identifying and isolating an agent useful for the treatment or prevention of neonatal necrotizing enterocolitis.